Clinical trials sponsored by Melanoma Institute Australia

Phase breakdown

Conditions studied

Recruiting trials led by Melanoma Institute Australia

• Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
  NCT03340129 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 9 locations
• Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
  NCT06999980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalised Immunotherapy Platform
  NCT06536257 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
  NCT06767306 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• The Multicentre Selective Lymphadenectomy Trial - 3
  NCT07049276 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 8 locations

Common questions

How many trials is Melanoma Institute Australia recruiting for?

Melanoma Institute Australia is the lead sponsor of 5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.